Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas is a research paper published in Neuro-Oncology Advances (2023). On theSindex it has a DataRank of 0. It has been cited 18 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: NS122096
National Institutes of Health
Grant: T32GM065841
Mayo Clinic Center for Individualized Medicine and CCaTS award
Grant: UL1TR002377
NIGMS NIH HHS
Grant: T32 GM145408
NCI NIH HHS
Grant: R37 CA276851
NCI NIH HHS
Grant: P30 CA015083
NINDS NIH HHS
Grant: R61 NS122096
NINDS NIH HHS
Grant: R33 NS122096
National Institutes of Health
Grant: 3UL1TR002377-04S5
Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Regan Theiler)
National Institutes of Health
Grant: 1R61NS122096-01A1
Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.
National Institutes of Health
Grant: 5T32GM065841-04
Medical Scientist Training Program at Mayo Clinic
FWCI
3.12
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords